First blood test for Alzheimer’s to be available in U.S. in June

Fujirebio Holdings Inc. will launch the first blood test for Alzheimer's diagnosis in the US in late June, following FDA clearance, potentially improving access to diagnosis and treatment for the nearly 7 million Americans affected. The test, designed for individuals 55 and older showing symptoms, detects amyloid buildup and offers a faster, less expensive alternative to PET scans and cerebrospinal fluid tests, which have previously hindered the rollout of new Alzheimer's drugs like Leqembi and Kisunla. The company plans to seek approvals in Japan and Europe, with partners pursuing regulatory clearance in China and India.

Analysis

Fujirebio Holdings Inc., a unit of Japan’s H.U. Group Holdings Inc., is set to launch the first FDA-cleared blood test for Alzheimer's disease in the US from late June, a development with positive sentiment (score 0.7) and moderate anticipated market impact (score 0.6). This test, designed for individuals aged 55 and older exhibiting symptoms, detects amyloid protein—a hallmark of Alzheimer's—in approximately 30 minutes and at a fraction of the cost of traditional PET scans or cerebrospinal fluid tests. This innovation is significant as it addresses a critical need for more accessible and less invasive diagnostic tools for the nearly 7 million Americans affected by Alzheimer's, potentially accelerating the identification and treatment of patients. The availability of this test is expected to facilitate the broader adoption of new Alzheimer's drugs, such as Eisai Co. and Biogen Inc.'s Leqembi and Eli Lilly & Co.’s Kisunla, whose rollouts have been hampered by the limitations of existing diagnostic methods. Fujirebio plans an initial deployment in about 50 specialized US research institutes and hospitals, leveraging partnerships with larger firms like Beckman Coulter Inc. for development and manufacturing. The company is also pursuing global expansion, with plans to seek regulatory approval in Japan by August, Europe within the year, and through partners in China (submission expected next year) and India (data already filed by Agappe Diagnostics Ltd.), reflecting a strategy to benefit from supplying raw materials to established market players.

Key Decisions for Investors

• Investors should monitor pharmaceutical companies such as Eisai Co., Biogen Inc. (BIIB), and Eli Lilly & Co., as Fujirebio's less invasive and more cost-effective blood test is likely to expand the addressable patient population for their Alzheimer's treatments, potentially boosting drug uptake and revenues.
• Consider the competitive shift within the Alzheimer's diagnostic market; the new blood test may present challenges for providers of PET scans and cerebrospinal fluid tests, while creating opportunities for Fujirebio's parent, H.U. Group Holdings Inc., and its strategic partners like Beckman Coulter Inc.
• Track Fujirebio's progress with regulatory approvals and market adoption in key international markets including Japan, Europe, China, and India, as successful expansion could significantly increase the test's reach and financial impact for involved entities.